drugset / Trial / NCT06117020

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

NCT06117020 ↗

Phase 1 Completed 89 enrolled Motric Bio
RandomizedParallel-groupQuadruple-blindOther

Summary

To assess the safety and tolerability of single and multiple doses of MTR-601 in normal healthy volunteers under fed and fasted conditions. To evaluate the plasma and urine pharmacokinetics (PK) of MTR-601. To evaluate the pharmacodynamic (PD) effects of MTR-601 on muscle strength and muscle accumulation of MTR-601 by muscle biopsy and other potential mechanistic, predictive and PD markers of MTR-601.

Timeline

Start
2023-09-11
Primary completion
2024-10-16
Completion
2024-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject MTR-601 Unknown 10 mg Oral
Subject MTR-601 Unknown 20 mg Oral
Subject MTR-601 Unknown 80 mg Oral